Inventiva S.A.

IVA

$4.84

-0.41%

N/A-$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. ...

Financial Highlights of IVA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

35.1%

Net Margin

-7899.6%

P/E Ratio

-2.16x

n/a

Debt / Equity

-2.10

n/a

Current Ratio

3.16

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

35.1%

Net Margin

-7899.6%

P/E Ratio

-2.16x

Debt / Equity

-2.10

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	100.0%	140.1%	100.1%	100.0%	33.7%	—
Operating MarginOperating income as a percentage of revenue.	-1242.6%	-468.9%	-587.7%	-1060.6%	-2921.0%	—
Net MarginNet income as a percentage of revenue.	-1183.5%	-445.6%	-631.8%	-2002.7%	-7587.8%	—
EBITDA MarginEBITDA divided by revenue.	-1258.0%	-462.2%	-583.9%	-1810.4%	-2858.6%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-1174.8%	-445.8%	-628.4%	-1999.4%	-7636.1%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	5.06	3.47	0.96	0.92	3.15	—
Quick RatioLiquid assets divided by current liabilities.	5.04	3.45	0.95	0.92	3.15	—
Cash RatioCash and equivalents divided by current liabilities.	3.79	2.83	0.54	0.80	1.28	—
Debt / AssetsDebt as a share of total assets.	8.3%	29.8%	53.9%	45.7%	23.9%	—
Debt / EquityDebt compared with shareholder equity.	0.11	0.76	-1.17	-0.51	-2.05	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.36x	43.65x	1.11x	0.76x	0.49x	—
Inventory TurnoverHow often inventory is sold in a year.	2.59x	2.67x	-0.06x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.07x	0.05x	-0.00x	0.12x	0.11x	—
Asset TurnoverRevenue generated per dollar of assets.	0.03x	0.10x	0.25x	0.08x	0.02x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.04x	0.14x	0.47x	-1.64x	0.06x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-10.76x	-3.40x	-1.86x	-0.60x	-2.55x	—
P/B RatioPrice paid for each dollar of book value.	6.02x	4.07x	-6.40x	-1.04x	-29.92x	—
P/S RatioPrice paid for each dollar of sales.	127.57x	15.18x	11.73x	12.09x	193.76x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-11.11x	-4.06x	-2.50x	-1.29x	-8.58x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

DelpharmUnnamed single-source suppliers (API components & materials)Unnamed Contract Research Organizations (CROs)European Investment Bank (EIB)Unnamed specialty chemical & intermediate suppliersCatalys Pacific

Downstream

Sino Biopharmaceutical Ltd / Chia Tai Tianqing Pharmaceutical Group (CTTQ)HKEx:1177Hepalys Pharma, Inc.Biossil, Inc.AbbVie Inc.NYSE:ABBVBoehringer Ingelheim International GmbH

Proxies

Madrigal Pharmaceuticals, Inc.NASDAQ:MDGL Viking Therapeutics, Inc.NASDAQ:VKTX Sino Biopharmaceutical LimitedHKEx:1177 Akero Therapeutics, Inc.NASDAQ:AKRO

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Inventiva S.A.

Financial Highlights of IVA

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of IVA

Upstream

Downstream

Proxies

Financial Highlights of IVA

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of IVA

Upstream

Downstream

Proxies